Applied DNA Sciences (APDN) Receives a Buy from Maxim Group

By Austin Angelo

In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Buy rating on Applied DNA Sciences (APDNResearch Report), with a price target of $8.00. The company’s shares closed last Monday at $3.94, close to its 52-week low of $3.52.

According to, Vendetti is a 1-star analyst with an average return of -0.6% and a 43.9% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Milestone Scientific, Ra Medical Systems, and Sensus Healthcare.

Currently, the analyst consensus on Applied DNA Sciences is a Moderate Buy with an average price target of $8.00.

See today’s analyst top recommended stocks >>

The company has a one-year high of $37.20 and a one-year low of $3.52. Currently, Applied DNA Sciences has an average volume of 729.4K.

Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of APDN in relation to earlier this year. Most recently, in September 2019, John Bitzer, a Director at APDN bought 196,661 shares for a total of $106,197.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Applied DNA Sciences, Inc. engages in the provision of security solutions. It offers molecular-based technology solutions and services that can help protect products, brands, supply chains, and intellectual property of companies, governments, and consumers from theft, counterfeiting, fraud, and diversion.